Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
BioSante Pharmaceuticals, Inc.
BioSante Pharmaceuticals Reports LibiGel® Status and Financial Results for 2008
April 4th, 2009
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced the status of LibiGel in development for the treatment of female sexual dysfunction and financial results for the year ended December 31, 2008. “BioSante had an excellent year in 2008. Our new product development was led by the initiation of three LibiGel Phase III clinical trials,” said Stephen M. Simes, BioSante’s president and chief executive officer. “These clinical trials continue to enroll subjects and make progress. LibiGel is BioSante’s transdermal testosterone gel in late-stage development for the treatment of female sexual dysfunction (FSD) in menopausal women. LibiGel’s development continues under a...
Source: Law & Health Weekly (2009-04-04)
|
